Is Jazz Pharmaceuticals PLC (JAZZ) Stock About to Get Hot Thursday?

The market has been high on Jazz Pharmaceuticals PLC (JAZZ) stock recently. JAZZ gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Jazz Pharmaceuticals PLC has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on JAZZ!

See Full JAZZ Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With JAZZ Stock Today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $165.48 as of 3:25 PM on Thursday, Apr 21, a decline of -$2.52, or -1.5% from the previous closing price of $168.00. The stock has traded between $165.07 and $169.89 so far today. Volume today is below average. So far 196,527 shares have traded compared to average volume of 500,719 shares.

More About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Click Here to get the full Stock Report for Jazz Pharmaceuticals PLC stock.